H.C. Wainwright has reiterated its Buy rating and maintained a $24.00 price target on Inventiva SA (NASDAQ: IVA) after assessing a poster presented at the Keystone Obesity Conference in Colorado. The stock was trading at $6.87 at the time of the note, and InvestingPro data shows gains of 209% over the past year and 126% over the last six months.
The poster, produced by Dr. Timo D. Müller’s research group at Helmholtz Munich in Germany, focused on what the research team described as a "unimolecular quintuple agonist." H.C. Wainwright interprets this work as important external validation of Inventiva’s scientific approach.
The study emphasized a next-generation conjugate that merges GLP-1R and GIPR co-agonists with the pan-PPAR pharmacology associated with lanifibranor, the lead candidate from Inventiva. According to the research firm’s summary of the poster, the conjugate’s mechanism relies on targeted delivery: the molecule selectively binds to cells expressing GLP-1R and GIPR, is internalized, and subsequently releases the lanifibranor component so it can act intracellularly.
Within H.C. Wainwright, analyst Ananda Ghosh preserved the firm’s positive stance on Inventiva, citing the Keystone presentation as supportive of the company’s therapeutic concept.
Beyond the poster and the analyst reaction to it, Inventiva has taken several notable financial and market steps. The company announced a $172.5 million equity financing to support its ongoing NATiV3 Phase 3 trial. Following that financing, Guggenheim adjusted its price target on Inventiva to $11 from $13 while retaining a Buy rating.
Inventiva also resumed trading on Euronext Paris after a temporary halt that was put in place to manage an American Depositary Shares offering in the United States.
Other analyst actions have produced a mix of perspectives. Leerink Partners initiated coverage with an Outperform rating and a $12 price target, specifically noting the potential of lanifibranor for treating metabolic dysfunction-associated steatohepatitis (MASH). UBS issued a Buy rating with the same $12 price target and cited what it called the blockbuster potential of lanifibranor.
Taken together, the Keystone presentation, the recent financing, and the flurry of analyst coverage illustrate growing interest in Inventiva and differing views on the valuation and commercial outlook for lanifibranor. H.C. Wainwright’s reaffirmation of a $24.00 target stands at the higher end of the range of cited price targets and reflects the firm’s interpretation of the scientific data as supportive of Inventiva’s approach.
Summary: H.C. Wainwright confirmed its Buy rating and $24.00 price target on Inventiva after a Keystone Obesity Conference poster by Helmholtz Munich that described a unimolecular quintuple agonist combining GLP-1R/GIPR co-agonism with pan-PPAR activity related to lanifibranor. Inventiva announced a $172.5 million equity financing for its NATiV3 Phase 3 trial and resumed trading on Euronext Paris following a temporary halt tied to its ADS offering. Other firms have provided a range of price targets and ratings, reflecting varied assessments of lanifibranor’s potential.